Paper528267
Resistance to adriamycin in multicellular spheroids.
Sutherland RM and 4 others. Int J Radiat Oncol Biol Phys, 1979. Cited by 237 papers, by iCite.
Cite this record
ConductScience Library. Resistance to adriamycin in multicellular spheroids. Papers, record 528267. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528267
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Mammary Neoplasms, Experimental | Major topic |
| Animals | |
| Cell Division | |
| Cell Survival | |
| Cells, Cultured | |
| Drug Resistance | |
| Female | |
| Hypoxia | |
| Mice | |
| Misonidazole |
Source PubMed
Cited by82
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 237 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39809466 | Mass Spectrometry-Based Applications of Spheroids in Cancer Biology. | Annu Rev Anal Chem (Palo Alto Calif) | 2025 | https://conductscience.org/library/papers/39809466 | PubMed |
| 36479072 | The magic bullet: Niclosamide. | Front Oncol | 2022 | https://conductscience.org/library/papers/36479072 | PubMed |
| 31893010 | Boyden chamber-based compartmentalized tumor spheroid culture system to implement localized anticancer drug treatment. | Biomicrofluidics | 2019 | https://conductscience.org/library/papers/31893010 | PubMed |
| 30564299 | Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression. | Oncotarget | 2018 | https://conductscience.org/library/papers/30564299 | PubMed |
| 30555545 | Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development. | Theranostics | 2018 | https://conductscience.org/library/papers/30555545 | PubMed |
| 26929788 | Targeting dormant micrometastases: rationale, evidence to date and clinical implications. | Ther Adv Med Oncol | 2016 | https://conductscience.org/library/papers/26929788 | PubMed |
| 26084404 | Mass spectrometry imaging of therapeutics from animal models to three-dimensional cell cultures. | Anal Chem | 2015 | https://conductscience.org/library/papers/26084404 | PubMed |
| 25971923 | Identification of novel drugs to target dormant micrometastases. | BMC Cancer | 2015 | https://conductscience.org/library/papers/25971923 | PubMed |
| 25337831 | Desmoplasia and chemoresistance in pancreatic cancer. | Cancers (Basel) | 2014 | https://conductscience.org/library/papers/25337831 | PubMed |
| 25186948 | Serine catabolism regulates mitochondrial redox control during hypoxia. | Cancer Discov | 2014 | https://conductscience.org/library/papers/25186948 | PubMed |
| 25027500 | State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. | ALTEX | 2014 | https://conductscience.org/library/papers/25027500 | PubMed |
| 24736530 | Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. | Sci Rep | 2014 | https://conductscience.org/library/papers/24736530 | PubMed |
| 24634853 | Tumor microenvironment and nanotherapeutics. | Transl Cancer Res | 2013 | https://conductscience.org/library/papers/24634853 | PubMed |
| 24591842 | Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. | Onco Targets Ther | 2014 | https://conductscience.org/library/papers/24591842 | PubMed |
| 24404028 | Microfluidic device for trapping and monitoring three dimensional multicell spheroids using electrical impedance spectroscopy. | Biomicrofluidics | 2013 | https://conductscience.org/library/papers/24404028 | PubMed |
| 23805101 | Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. | Front Pharmacol | 2013 | https://conductscience.org/library/papers/23805101 | PubMed |
| 23624217 | A novel tissue engineered three-dimensional in vitro colorectal cancer model. | Acta Biomater | 2013 | https://conductscience.org/library/papers/23624217 | PubMed |
| 23576741 | Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23576741 | PubMed |
| 23533463 | Chemistry and biology of essential oils of genus boswellia. | Evid Based Complement Alternat Med | 2013 | https://conductscience.org/library/papers/23533463 | PubMed |
| 22949815 | Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. | Int J Mol Sci | 2012 | https://conductscience.org/library/papers/22949815 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/528267
GET https://conductscience.org/api/papers/v1/528267/cited_by?page=2